Get rid of the fog and talk about the future-2019 China Medicine New Smart Forum was successfully held!

On December 28, 2019, under the guidance of China Pharmaceutical Materials Association, the "2019 China Pharmaceutical new wisdom forum" and the "new wisdom 2019 pharmaceutical industry annual value pioneer list award ceremony" jointly sponsored by Sina pharmaceutical and China Pharmaceutical Materials Association food and drug industry think tank were successfully held in Beijing The theme of this conference is "big waves chasing new wisdom gathering" In the form of "keynote speech + round table dialogue", industry experts and senior management of the enterprise made a profound analysis on the new development direction of the pharmaceutical industry in the next ten years and the new trend of future pharmaceutical reform, and witnessed the award ceremony of the annual value pioneer list of the pharmaceutical industry in 2019 In the keynote speech in the morning, Liu Changxiao, academician of Chinese Academy of engineering, said that many challenges faced by China's pharmaceutical industry in the next decade include the United States, which has outstanding innovation ability, and India, which is developing rapidly In the future, Indian pharmaceutical companies will transfer to China after occupying a stable share of generic drugs in the U.S market, and Indian enterprises have advantages in developing pharmaceutical market In addition, with the implementation of policies such as volume purchase and medical insurance negotiation, pharmaceutical enterprises are also facing great challenges in sales transformation In terms of pharmaceutical development, Liu Changxiao believes that innovation is still a key word of Chinese pharmaceutical industry in the next decade, and the trend of more openness to promote the development of pharmaceutical globalization is also unstoppable For example, with the implementation of the new drug management law and the increasing demand for Chinese medicine, it will promote the priority of original new drugs in China, and accelerate the speed of market review and approval Liu Changxiao, academician of Chinese Academy of Engineering Yu Mingde said that there is no absence of regulatory agencies for innovation and development of the pharmaceutical industry For example, the speed of approval of new drug registration by domestic drug regulatory agencies in the past has been widely criticized by the industry, but now remarkable progress has been made after the reform The queuing time of overseas varieties listed in the clinical urgent need list is now within three months from the average of 34 months in the past The positive changes in policies have also aroused the confidence of enterprises in R & D and innovation However, Yu Mingde also stressed that when making any policy, the government should fully consider the opinions of enterprises and the market, and all parties should fully study and discuss, so as to work together for the progress of China's pharmaceutical industry Yu Mingde, honorary president of China Pharmaceutical Industry Association Yu Mingde said that it is everyone's responsibility to create an environment In fact, whether the environment for the development of medicine is good or not has a direct relationship with each of us That is not to say that when someone else has created a good environment, I will enjoy it We should create and strive for it together Liu Xiaoping said that drug regulation has a specific functional attribute, which is to ensure the safety of drugs However, drug regulation is not for the purpose of regulation The ultimate purpose of regulation is to improve the development level of our pharmaceutical industry as a whole, which is to ensure drug safety in a fair and just market environment Liu Xiaoping, former deputy inspector of the Department of pharmaceutical supervision of the State Food and Drug Administration "Of course, at the same time, we should continue to promote the development of the pharmaceutical industry and promote the continuous innovation of the industry, so as to provide the people with the drugs needed in a timely manner and with reliable efficacy I think this is a new mission and new demand for drug regulation in the new era." Liu Xiaoping told the audience Yang Donghui also expressed his views on the way of research and development of China's innovative pharmaceutical enterprises Taking Arnold pharmaceutical as an example, he said that Arnold pharmaceutical is a global pharmaceutical enterprise based in China The Chinese market is not only the growth rate of Chinese pharmaceutical enterprises is very fast, but also foreign pharmaceutical enterprises pay more and more attention to the Chinese market, including the current policies and many foreign drugs It is well used in China Yang Donghui, co-founder, director and senior vice president of Arnold pharmaceutical In fact, for the innovation and development of traditional Chinese medicine, the construction of scientific and technological team of traditional Chinese medicine is very important Pu Chuanwen said that at present, there are more than 20000 scientific and technological personnel of traditional Chinese medicine in China, and only 1800 scientific and technological personnel in central units How can such a small team undertake the task of inheritance and innovation of traditional Chinese medicine? It is necessary to speed up the construction of scientific and technological team of traditional Chinese medicine, and to absorb scientific researchers from all disciplines to participate in the team, so as to truly promote the inheritance and innovation of traditional Chinese medicine to accelerate the pace and go further Pu Chuanwen, former executive vice president and deputy editor in chief of China traditional Chinese medicine newspaper 2020 will usher in a new wave of capital, technology and retail in the pharmaceutical industry It is an important task for enterprises to learn how to stand firm when the new wave comes For the pharmaceutical industry in 2019, capital financing is in a cold wind According to relevant statistics, this year's total financing of the pharmaceutical industry is less than half of that of last year In 2019, there were 39 financing events in the domestic medical service industry, with a total financing amount of nearly 5.3 billion yuan Compared with 84 financing events in 2018 and 11.6 billion yuan of financing amount, the total financing amount decreased by more than half So in the coming 2020, what will be the state of investment in the pharmaceutical industry? Which enterprises will be more favored by investors in the future? Li Qiushi, partner in charge of gotega investment group, said in a keynote speech in the afternoon that at present, there are four or five thousand pharmaceutical companies in China Although most of them survive well, China will be polarized in the future with the long-term impact of 4 + 7 volume procurement, including the impact of the state's encouragement of innovative drugs First, a large number of innovative drug companies are involved in the Enterprises with layout in various fields, on the other hand, ordinary enterprises are either changed, integrated or withdrawn from the market For investment institutions, they will invest in outstanding large enterprises with long-term capital layout and long-term evolution As investors, they will pay more attention to the long-term R & D process and are more willing to wait for the results of innovation Li Qiushi, partner in charge of gotka Investment Group The technical development of the pharmaceutical industry is also changing with each passing day, but it is also facing the impact of the new wave Gu Weijun, vice president and Secretary General of China Pharmaceutical Equipment Engineering Association, said in his speech that all enterprises pursuing progress in technology have succeeded in embracing advanced technical regulations and technical standards In the next step, enterprises should pay more attention to the power of standards, because standards are the cornerstone of change, Actively participate in the construction of laws and standards, actively participate in the construction of regulations and guidelines, and promote the core competitiveness of enterprises with standardization, which is the most important thing for many enterprises, especially investment enterprises Gu Weijun, vice president and Secretary General of China Medical Equipment Engineering Association In addition, the pharmaceutical retail industry has also ushered in changes The current retail area of medicine is experiencing calm and rationality after experiencing the Internet plus baptism Chain drugstores have also changed their main direction of development with the help of the Internet They are more inclined to "new retail", that is, traditional retail uses the Internet to upgrade and build new core competitiveness Under the new retail, how to develop o2o? Xia Yu, CEO of Beijing Dekai Pharmaceutical Technology Co., Ltd., said in his speech that the proportion of drugs sold on the Internet will be increasing in the next few years Since the promulgation of the drug administration law, the Internet sales of drugs have gradually opened up, which is a great opportunity for some traditional pharmacies Xia Yu, CEO of Beijing Dekai Pharmaceutical Technology Co., Ltd And Jin enlin, general manager and head of strategy and investment of JD health and medicine department, said in the keynote speech of "the fourth terminal, not only retail", that: the growth rate of pharmaceutical e-commerce is very fast, which has become a new channel that industry, commerce and retail have to pay attention to In the future, medical e-commerce will combine services and goods more closely, and integrate online and offline Jin enlin, general manager and head of strategy and investment of Jingdong health and medicine department In the afternoon round table dialogue, Bai Yu, founder and chairman of rehabilitation home health management group Co., Ltd., put forward the question about brand innovation of China's pharmaceutical industry to the dialogue guests Bai Yu, founder and chairman of rehabilitation home health management group Co., Ltd Bai Huiliang, former president of China OTC Association, took OTC industry as an example In early years, some OTC pharmaceutical enterprises did not pay enough attention to brand building, and there were some confusion in the whole OTC industry However, from the 11th Five Year Plan period, the OTC industry recognized the importance of brand, so in the coming 2020, China's OTC industry will present a great development space Bai Huiliang, former president of China OTC Association Jin enlin, general manager and head of strategy and investment of Jingdong health and medicine department, told the audience at the round table: "although Jingdong has its own business in drug online retail, it will never have conflicts with the third-party businesses on the platform, and Jingdong will cooperate more with businesses We hope that businesses can sell better drugs in combination with offline stores We will never have a harvesting platform " For OTC enterprises, innovation is not only the renewal of sales mode, but also the transformation of a whole set of development concepts Ma Sibao, assistant to the vice chairman of Qingdao Shuangjing Pharmaceutical Co., Ltd and general manager of brand e-commerce marketing department, talked about the innovation road of their own enterprises in the dialogue At present, Shuangjing pharmaceutical has two brand models: Inheritance and innovation For example, as for inheritance, Shuangjing pharmaceutical has a cod liver oil product, which won the national quality award twice in the 1980s Now Shuangjing pharmaceutical is actively exploring these advantages For example, last year, it worked with CCTV to create books about the growth of cod liver oil Ma Sibao, deputy chairman assistant and general manager of brand e-commerce marketing department of Qingdao Shuangjing Pharmaceutical Co., Ltd In fact, both inheritance and innovation need a lot of financial support As mentioned above, 2019 medical service financing is only half of that of last year Zhang Ying, director of Guangfa financing (Hong Kong) Co., Ltd., expressed her views on this in the round table dialogue He said that the capital market is much calmer now than before, but more and more quality enterprises will come out in the future, and the final money will come I'll go back to where I should be Zhang Ying, director of Guangfa Finance (Hong Kong) Co., Ltd At the meeting, Sina pharmaceutical and CCID consultants also jointly released the 2019 China biomedical industry development report, which described the development process of China's biomedical industry in 2019 from the perspective of hot events, market scale, R & D innovation, investment and financing data, and predicted the industry development trend It is available to pay attention to the reply "report" of "Sina pharmaceutical" Full text of 2019 China biomedical industry development report At this conference, the final list of awards for the three-month "new wisdom 2019 pharmaceutical industry annual value pioneer list" selection activity has also been announced, and an award ceremony has been held This year is the fourth year that Sina's annual general evaluation list of medicine is held, and it is also the first time that sina has cooperated with the think tank of food and drug industry of China Pharmaceutical Materials Association, aiming to discover the explorers and practitioners who have real value creation, maintain innovation vitality, and have a positive impact on industrial change through quantitative data indicators, expert review and online voting.